Investing.com - Teva ADR (NYSE: TEVA) reported fourth quarter EPS of $0.71, $0.02 better than the analyst estimate of $0.69. Revenue for the quarter came in at $4.23B versus the consensus estimate of $4.1B.
Guidance
Teva ADR sees FY 2025 EPS of $2.35-$2.65 versus the analyst consensus of $2.78.
Teva ADR sees FY 2025 revenue of $16.80B-$17.40B versus the analyst consensus of $17.09B.
Teva ADR's stock price closed at $21.53. It is up 16.69% in the last 3 months and up 83.55% in the last 12 months.
Teva ADR saw 2 positive EPS revisions and 3 negative EPS revisions in the last 90 days. See Teva ADR's stock price’s past reactions to earnings here.
According to InvestingPro, Teva ADR's Financial Health score is "great performance".
Check out Teva ADR's recent earnings performance, and Teva ADR's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar